Skip to main content
. 2022 Oct 25;29:10732748221129451. doi: 10.1177/10732748221129451

Figure 9.

Figure 9.

(A) The IC50 of rucaparib in multiple cancers (B) The mutations of MLL2 could improve the sensitivity of patients to Olaparib.